SPRINT Trial showed a 25% reduction in cardiovascular events with intensive blood pressure control.
Intensive blood pressure control in SPRINT Trial led to unexpected cognitive benefits, challenging existing guidelines.
Deep dives
Overview of the SPRINT Trial
The SPRINT Trial, published in 2015, involved over 9,000 high-risk participants aged 50 and above. The study randomized participants to intensive systolic blood pressure goal of less than 120 mm Hg versus a standard goal of 140 mm Hg. After about three years, the data revealed a significant 25% benefit in reducing fatal and non-fatal cardiovascular events, and a 25-30% decrease in all-cause mortality compared to the standard group.
Methodology and Blood Pressure Measurement
The SPRINT Trial included standard blood pressure measurement methodologies involving rest, proper cuff size, and valid instruments. The study utilized automated machines for unbiased measurements. Participants had monthly follow-ups initially, with the intensive group returning until reaching goal blood pressure. The trial recommended using specific drug classes like thiazide diuretics, calcium channel blockers, and RAS blockers, emphasizing correct dosages and combinations.
Impact on Cognitive Function
Surprisingly, the study showed a 15-20% reduction in mild cognitive impairment and dementia with the intensive blood pressure control approach, despite relatively short follow-up. The cognitive benefit was unexpected within the three-year span and prompted ongoing monitoring for further long-term impacts. The trial highlighted potential cognitive benefits beyond cardiovascular outcomes through improved blood pressure control.
Future Guidelines and Implications for Kidney Outcomes
The study's outcomes challenge existing hypertension guidelines by demonstrating benefits of targeting a lower systolic blood pressure goal. Insights from the SPRINT Trial suggest the need for ongoing research to assess long-term kidney outcomes and the impact of early and intensive blood pressure control strategies. The trial results indicate a potential delay in observing kidney benefits, emphasizing the importance of continued monitoring and exploration in nephrology research.
In Episode 12, Dr. William Cushman, co-investigator of the 2015 SPRINT (Systolic Blood Pressure Intervention) Trial, joins us for a discussion all about hypertension trials, their long history, and what's ahead for research in this space. Too young to remember SPRINT or looking for a "CliffsNotes" of HTN trials? This episode's for you!